Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-integrin α3 activating antibody
- Development stage
- Preclinical
- Lead developer
- Allosite Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
anti-integrin α3 activating antibody is a preclinical-stage monoclonal antibody being developed by Allosite Therapeutics in collaboration with Rush University Medical School and the University of Texas Medical Branch. It is designed as an allosteric agonist of the integrin α3β1 heterodimer, which is highly expressed on kidney podocytes and is essential for their attachment to the glomerular basement membrane. By binding to the α3 head domain and stabilizing the active conformation of integrin α3β1, the antibody enhances podocyte adhesion, preserves cytoskeletal stability, and prevents podocyte detachment and loss. This therapeutic approach is being investigated for the treatment of glomerular diseases, specifically focal segmental glomerulosclerosis (FSGS) and chemotherapy-induced nephrotoxicity.
- Other names
- anti-integrin alpha-3 activating antibodyanti-integrin α3β1 activating antibodyanti-integrin α3β1 agonist antibodyintegrin α3β1 activating antibodyintegrin α3β1 agonist antibody
02
Targets
α3β1 (Integrin alpha 3 beta 1)ITGB1 (Integrin beta-1)Integrin (Integrin family)
Beyond the preview
Go deeper on anti-integrin α3 activating antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-integrin α3 activating antibody.